21731-57-7

Basic information

• Product Name: 4-(Methylsulphonyl)benzene-1,2-diamine
• Synonyms: 4-(Methylsulphonyl)benzene-1,2-diamine;1,2-Diamino-4-(methylsulphonyl)benzene, 3,4-Diaminophenyl methyl sulphone, 4-(Methylsulphonyl)phenylene-1,2-diamine;4-(Methylsulfonyl)benzene-1,2-diaMine;4-Methanesulfonylbenzene-1,2-diaMine
• CAS NO: 21731-57-7
• Molecular Formula: C₇H₁₀N₂O₂S
• Molecular Weight: 186
• Mol File: 21731-57-7.mol
• Article Data: 8

Chemical Properties

• Melting Point: 156-158 °C
• Boiling Point: 457.3±45.0 °C(Predicted)
• Appearance: /
• Density: 1.371±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 2.22±0.10(Predicted)
• CAS DataBase Reference: 4-(Methylsulphonyl)benzene-1,2-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Methylsulphonyl)benzene-1,2-diamine(21731-57-7)
• EPA Substance Registry System: 4-(Methylsulphonyl)benzene-1,2-diamine(21731-57-7)

Safety Data

• Hazardous Substances Data: 21731-57-7(Hazardous Substances Data)

Usage

General Description

4-(Methylsulphonyl)benzene-1,2-diamine is a chemical compound that is also known as Methylsulfonylbenzenediamine. It is an amine compound that contains a benzene ring with a methylsulfonyl group attached to the 4th carbon and an amine group attached to the 1st and 2nd carbons. 4-(Methylsulphonyl)benzene-1,2-diamine is primarily used in the synthesis of pharmaceuticals and specialty chemicals. It has also shown potential as an anti-inflammatory and anti-cancer agent in early research studies. Due to its versatile chemical structure, 4-(Methylsulphonyl)benzene-1,2-diamine has various potential applications in the pharmaceutical and chemical industries.

Upstream product

• 121444-20-0 5-(methylsulfonyl)-2-nitroaniline 
• 2369-11-1 5-fluoro-2-nitroaniline 
• 31431-10-4 2-amino-4-methylthio-1-nitrobenzene 
• 453-72-5 1-fluoro-4-methanesulfonyl-2-nitrobenzene 
• 21731-56-6 1-Amino-4-methylsulphonyl-2-nitrobenzene 
• 54029-50-4 acetic acid-(4-methanesulfonyl-2-nitro-anilide) 
• 97-07-4 1-chloro-4-methanesulfonyl-2-nitrobenzene 
• 98-57-7 4-chlorophenyl methyl sulfone 
• 23153-09-5 1-amino-4-methylthio-2-nitrobenzene 

Downstream Products

• 1192251-51-6 2-biphenyl-4-yl-6-(methylsulfonyl)-1H-benzimidazole 
• 1192251-64-1 6-(methylsulfonyl)-2-[4-(2-thienyl)phenyl]-1H-benzimidazole 
• 1192251-88-9 {4-[6-(methylsulfonyl)-1H-benzimidazol-2-yl]phenyl}boronic acid 
• 1438246-03-7 C₂₅H₂₄N₄O₅S 
• 1438246-34-4 C₂₅H₂₄N₄O₅S 
• 1192251-77-6 6-(methylsulfonyl)-2-(6-phenylpyridazin-3-yl)-1H-benzimidazole 
• 1192251-78-7 6-(methylsulfonyl)-2-(2-phenylpyrimidin-5-yl)-1H-benzimidazole 
• 1192251-87-8 2-(4-bromophenyl)-6-(methylsulfonyl)-1H-benzimidazole 
• 54393-93-0 1,2-bis-(3-carbomethoxy-2-thioureido)-4-methylsulfonylbenzene 

Relevant articles and documents

Benzimidazole derivatives, their preparation and their application in medicine and pharmacology (by machine translation)

The invention relates to a new control or inhibit indocyanine 2, 3 - dioxygenase (IDO) activity of the benzimidazole derivatives, their preparation and their application in medicine and pharmacology. Specifically, the invention relates to a compound of general formula (I) compound of formula and its pharmaceutically acceptable salt, containing the compound or its pharmaceutically acceptable salt of the pharmaceutical composition, the use of the compound or its pharmaceutically acceptable salts for treating and/or preventing the relevance of the IDO-mediated disease, especially a tumor of the method and the compound or its pharmaceutically acceptable salts thereof. The invention also relates to the compound or its pharmaceutically acceptable salt or containing the compound or its pharmaceutically acceptable salts for the preparation of a pharmaceutical composition for treating and/or preventing the relevance of the IDO-mediated disease, in particular of the use of the drug in the tumor. Wherein the general formula (I) of each substituent is as defined in the specification. (by machine translation)

IMIDAZOLE DERIVATIVES

Described herein are compounds of formula I. The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

Synthesis of 2-[[(4-fluoroalkoxy-2-pyridyl)methyl]sulfinyl]-1H-benzimidazoles as antiulcer agents

-